ObjectivesThe treat-to-target (T2T) concept has been applied successfully in several inflammatory rheumatic diseases. Gout is a chronic disease with a high burden of pain and inflammation. Because the pathogenesis of gout is strongly related to serum urate levels, gout may be an ideal disease in which to apply a T2T approach. Our aim was to develop international T2T recommendations for patients with gout.MethodsA committee of experts with experience in gout agreed upon potential targets and outcomes, which was the basis for the systematic literature search. Eleven rheumatologists, one cardiologist, one nephrologist, one general practitioner and one patient met in October 2015 to develop T2T recommendations based on the available scientific evidence. Levels of evidence, strength of recommendations and levels of agreement were derived.ResultsAlthough no randomised trial was identified in which a comparison with standard treatment or an evaluation of a T2T approach had been performed in patients with gout, indirect evidence was provided to focus on targets such as normalisation of serum urate levels. The expert group developed four overarching principles and nine T2T recommendations. They considered dissolution of crystals and prevention of flares to be fundamental; patient education, ensuring adherence to medications and monitoring of serum urate levels were also considered to be of major importance.ConclusionsThis is the first application of the T2T approach developed for gout. Since no publication reports a trial comparing treatment strategies for gout, highly credible overarching principles and level D expert recommendations were created and agreed upon.
ObjectiveThere is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout.MethodsA content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions.ResultsThe content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: ‘asymptomatic hyperuricaemia’, ‘asymptomatic monosodium urate crystal deposition’, ‘asymptomatic hyperuricaemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus).ConclusionConsensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.
Consensus is that the following domains be considered mandatory for acute gout studies: pain, joint swelling, joint tenderness, patient global, physician global, functional disability; and for chronic gout studies: serum urate, gout flares, tophus regression, health-related quality of life, functional disability, pain, patient global, physician global, work disability and joint inflammation. Several additional domains were considered discretionary.
First attacks of gout may precede the diagnosis of metabolic abnormalities and associated diseases, and provids a unique opportunity to diagnose, prevent, and/or retard long-term complications in these patients.
Objective To investigate the factors associated with discordance between patient and physician on the presence of a gout flare. Methods Patients’ self-reports of current gout flares were assessed with the question, ‘Are you having a gout flare today?’ which was then compared with a concurrent, blinded, physician’s assessment. Based on agreement or disagreement with physicians on the presence of a gout flare, flares were divided into concordant and discordant groups, respectively. Within the discordant group, two subgroups—patient-reported flare but the physician disagreed and physician-reported flare but the patient disagreed—were identified. The factors associated with discordance were analysed with multivariable logistic regression analysis. Results Of 268 gout flares, 81 (30.2%) flares were discordant, with either patient or physician disagreeing on the presence of a flare. Of the discordant flares, in 57 (70.4%) the patient reported a flare but the physician disagreed. In multivariable logistic regression analysis adjusted for demographics, disagreement among patients and physicians on the presence of a gout flare was associated with lower pain scores at rest [odds ratio (OR) for each point increase on 0–10 point pain scale 0.81 (95% Wald CI 0.73, 0.90), P < 0.0001] and less presence of joint swelling [OR 0.24 (95% CI 0.10, 0.61), P = 0.003] or joint warmth [OR 0.39 (95% CI 0.20, 0.75), P = 0.005]. Conclusion Although patients and physicians generally agree about the presence of gout flare, discordance may occur in the setting of low pain scores and in the absence of swollen or warm joints.
ObjectiveTo develop a Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout, with the goal of increasing public understanding and awareness, and ensure consistent and understandable messages about gout.MethodsA G-CAN working group that included patients, physicians and nongovernmental organisation (NGO) representatives was formed to develop a common language definition of gout for use with the public, media, healthcare providers and stakeholders. A literature search and interviews with patients, healthcare workers and stakeholders informed development of the definition. Following consultation with G-CAN members and partners, the definition was endorsed by the G-CAN board.ResultsThe G-CAN common language definition of gout describes the epidemiology, pathophysiology, symptoms and impact, risk factors, comorbidities, management and healthcare and workforce considerations. Detailed information is provided to support the content of the definition. After the publication of the English-language version, the definition will be available for translation into other languages by G-CAN members.ConclusionG-CAN has developed a concise and easily understandable statement describing gout in language that can be used in conversations with the lay public, media, NGOs, funders, healthcare providers and other stakeholders.
Background:Atherosclerotic cardiovascular diseases (ASCVD), metabolic syndrome and hyperuricemia due to an increment in their incidence world-wide, but information regarding the 10-year estimated risk in gout vs. healthy subjects is scarce.Objectives:To assess baseline the 10-year cardiovascular risk and high-risk status in gout patients compared to healthy controls.Methods:Data from 494 gout paired to controls in a ratio of 1:1 matched with age, sex and body mass index (BMI) and stratified by normal (≤ 24.9 Kg/m2), overweight (25 - 29.9 Kg/m2) and obese (≥30 Kg/m2). Controls were asymptomatic subjects attending a preventive clinic in Mexico City. We used the Framingham Risk Score for Coronary Heart Disease (FRS-CHD) and the 2013 American College of Cardiology/American Heart Association (2013 ACC/AHA). Additionally, high risk status was defined according to pre-defined cutoff points for FRS-CHD (≥ 20%) and ACC/AHA 2013 (≥7.5%).Results:Data from 494 gout and 494 controls. Gout patients were male 97.4%, 47 (SD ± 13) years, mean BMI of 28.4 (SD ± 4.31) Kg/m2. Age, sex, and BMI and subgroups were equilibrated (p=NS). Gout patients had higher 10-year estimated risk vs. controls nevertheless, only FRS-CHD reached statistically significant difference with 9.38 vs. 7.5 ± 5.74 (p<0.001); For 2013 ACC/AHA 4.94 ± 6.16 vs. 5.23 ± 6.78, (p=0.49). Further stratification by BMI groups revealed that subjects with gout in normal and overweight categories were had higher risk vs. controls with FRS-CHD score of 8.86 ± 8.05 vs. 6.53 ± 6.41 (p=0.03) and 9.37 ± 7.72 vs. 7.89 ± 5.58 (p=0.01), respectively. No differences for 2013 ACC/AHA in global and BMI-stratified comparisons. Proportion of high-risk subjects were similar in both groups regardless of BMI category: for FRS-CHD 7.5 vs 4.7% (p=0.06) and 2013 ACC/AHA with 21.5 vs. 17.8% (p=0.14).Conclusion:Normal BMI or overweight Mexican patients with gout may be at higher 10-year estimated cardiovascular risk compared to matched age, gender and BMI healthy controls. Obese gout subjects are at high risk with non-statistical significance scores for FRS-CHD or 2013 ACC/AHA compared to controls.References:[1]Acosta-Cázares B, Escobedo-de la Peña J. High burden of cardiovascular disease risk factors in Mexico: An epidemic of ischemic heart disease that may be on its way?. American Heart Journal. 2010;160:230-6.[2]Sánchez Rodríguez A, Moreno-Del Castillo C, Prado Anaya CA et al. ESTIMATED 10-YEAR CARDIOVASCULAR RISK WITH FRAMINGHAM RISK AND 2013 ACC/AHA IN GOUT AND HEALTHY MEXICAN SUBJECTS: A CASE-CONTROL STUDY WITH A PROPENSITY SCORE-MATCHED ANALYSIS J Clin Rheumatol: 2019;25:S1–S96.[3]Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity cluster in people with gout: an observational cohort study with linked medial record review. Rheumatology (Oxford). 2018 Apr 17.[4]Andrés M, Bernal JA, Sivera F, Quilis N, Carmona L, Vela P, Pascual E. Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. Ann Rheum Dis. 2017;76:1263-8.Disclosure of Interests:None declared.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.